Home|Best-Bschool-in-india-2018

DSIJ Mindshare

First patient free of cancer: This stock to benefit from big breakthrough in cancer treatment - Indigenous CAR-T cell therapy! First patient free of cancer: This stock to benefit from big breakthrough in cancer treatment - Indigenous CAR-T cell therapy!

First patient free of cancer: This stock to benefit from big breakthrough in cancer treatment - Indigenous CAR-T cell therapy!

India's entry into the CAR T-cell therapy arena marks a pivotal moment in the global fight against cancer.

DSIJ Intelligence-3 0 1865 Article rating: 3.9

In this landscape of innovation, companies like Laurus Lab Ltd stand out as key players driving progress in the transformative cell and gene therapy space. Their strategic collaborations and advancements in product development hold promise for improving treatment outcomes and enhancing accessibility for patients

Read more
This mid-cap multibagger Pharma company signs MOA with IIT Kanpur for novel gene therapy assets! This mid-cap multibagger Pharma company signs MOA with IIT Kanpur for novel gene therapy assets!

This mid-cap multibagger Pharma company signs MOA with IIT Kanpur for novel gene therapy assets!

The company delivered exceptional returns of 251 per cent over the past 3 years.

DSIJ Intelligence 0 11404 Article rating: 3.8

The company delivered exceptional returns of 251 per cent over the past 3 years, while over the past 5 years, it provided remarkable returns of 242 per cent.    

Read more
This mid-cap multibagger company invests in cell and gene therapy company ImmunoACT! This mid-cap multibagger company invests in cell and gene therapy company ImmunoACT!

This mid-cap multibagger company invests in cell and gene therapy company ImmunoACT!

Through this collaboration, the company aims to bring CAR-T therapy to Indian patients at an affordable price, filling the gap in access to this novel treatment option.

DSIJ Intelligence 0 9776 Article rating: 3.3

CAR-T therapy has shown significant success in the western world as a promising treatment option. However, this innovative technology is currently unavailable in India. Through this collaboration, the company aims to bring CAR-T therapy to Indian patients at an affordable price, filling the gap in access to this novel treatment option. 

Read more
All eyes here: Futures and Options traders must take note of these changes! All eyes here: Futures and Options traders must take note of these changes!

All eyes here: Futures and Options traders must take note of these changes!

While these changes will be effective from October 28 (a day after October expiry), the contracts, for which they will be applicable, will vary. Here is a quick summary: 

DSIJ Intelligence-3 0 2284 Article rating: 4.5

As per NSE circular dated September 30, a total of 37 stocks will see changes in their F&O lot sizes due to the relevant price movements.  

Read more
RSS
123
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

SEBI Registered Research Analyst Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INH000006396
Validity: Oct 05, 2018 - Perpetual
BSE Enlistment No. 5307

SEBI Registered Investment Adviser Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INA000001142
Validity: Aug 19, 2019 - Perpetual
BSE Enlistment No. 1346

Registered and Correspondence Office Address :
DSIJ PVT LTD. Office No - 409,
Solitaire Business Hub, Kalyani Nagar, Pune - 411006
Tel: +91 022-43476012/13/14/15 | Email: service@dsij.in
CIN No.: U22120MH2003PTC139276
GST No.: 27AACCR4303G1ZP

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR

Disclaimer: "Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors"

Investment in securities market is subject to market risks. Read all the related documents carefully before investing.

Any act of copying, reproducing, or distributing the content whether wholly or in part, for any purpose without the permission of DSIJ is strictly prohibited and shall be deemed to be copyright infringement.

Disclosures | Terms & Conditions | Privacy Statement | WhiteList